Zynerba delays genetic disorder drug data on enrollment challenge (updated)

Zynerba Pharmaceuticals

21/12/2022 12:29

(Adds background)
       Dec 21 (Reuters) - Zynerba Pharmaceuticals Inc  ZYNE.O 
on Wednesday delayed the timeline for reporting key data from a
trial of its cannabis-based drug to treat a rare genetic
disorder, citing difficulties in enrolling patients amid a rise
in respiratory illnesses.
    It now expects to present results from the trial in first
half of 2024 from second half of 2023.
    In October, U.S. doctors had warned that a surge in cases of
respiratory syncytial virus (RSV) is coinciding with an increase
in COVID transmission and an earlier-than-normal flu season,
raising the specter of a "tripledemic" of respiratory illness
this winter.
    For the week ended Dec. 10, 4,391 cases of RSV were detected
in the United States, according to U.S. Centers for Disease
Control and Prevention.  
 (Reporting by Khushi Mandowara in Bengaluru; Editing by Krishna
Chandra Eluri)
 ((Khushi.Mandowara@thomsonreuters.com;))